articleTop 1% cited
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
The Lancet Oncology · 2021 · Vol. 22(2) · pp. 198–211
Luis Paz‐Ares✉(Hospital Universitario 12 De Octubre)Tudor–Eliade Ciuleanu(Institute of Oncology Prof. Dr. Ion Chiricuta)Manuel Cobo(Instituto de Investigación Biomédica de Málaga)Michael SchenkerBogdan ŻurawskiJ. Menezes(Hospital Nossa Senhora da Conceição)Eduardo Richardet(Instituto Oncológico de Córdoba)Jaafar Bennouna(Inserm)Enriqueta Felip(Vall d'Hebron Hospital Universitari)Óscar Juan(Hospital Universitari i Politècnic La Fe)Aurelia Alexandru(Institutul Oncologic Bucuresti)Hiroshi Sakai(Saitama Cancer Center)Alejo Lingua(Instituto Médico Río Cuarto)Pamela Salman(Fundación Arturo López Pérez)Pierre-Jean Souquet(Hôpital Lyon Sud)Pedro De Marchi(Hospital de Câncer de Barretos)Claudio Martín(Instituto Alexander Fleming)M. Pérol(Centre de Recherche en Cancérologie de Lyon)Arnaud Scherpereel(Inserm)Shun Lü(Shanghai Chest Hospital)Thomas John(Austin Hospital)David P. Carbone(The Ohio State University)S. Meadows–Shropshire(Bristol-Myers Squibb (United States))Shruti Agrawal(Bristol-Myers Squibb (United States))Abderrahim Oukessou(Bristol-Myers Squibb (United States))Jinchun Yan(Bristol-Myers Squibb (United States))Martin Reck(German Center for Lung Research)
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentIpilimumabNivolumabMedicineClinical endpointInternal medicineLung cancerChemotherapyInterim analysisPhases of clinical researchOncology
MeSH terms
IpilimumabNivolumabAgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingTreatment OutcomeDisease-Free Survival
Funding
- Bristol-Myers Squibb
Citations
1,333
FWCI
96.52
field-weighted impact
References
30
Percentile
100%
vs. same field & year
Citations per year
References
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
Cell Death and Differentiation · 2013 · 925 citations
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
New England Journal of Medicine · 2016 · 9,911 citations
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
New England Journal of Medicine · 2018 · 6,460 citations
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
The Lancet Oncology · 2019 · 1,645 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.